Zoledronic acid aggravates kidney damage during ischemia reperfusion injury in rat

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 34, Issue 1, 2015, Pages 53-61

  Sehitoglu, Ibrahim ^a   Tumkaya, Levent ^a   Bedir, Recep ^a   Kalkan, Yildiray ^a   Cure, Medine Cumhur ^a   Yucel, Ahmet Fikret ^a   Zorba, Orhan Unal ^a   Yuce, Suleyman ^b   Cure, Erkan ^a  

^a RECEP TAYYIP ERDOGAN UNIVERSITY   (Turkey)

^b Internal Medicine Kumru State Hospital   (Turkey)

Author keywords

Carbonic anhydrase II; Interleukin 6; Ischemia reperfusion; Kidney; Zoledronic acid

Indexed keywords

CARBONATE DEHYDRATASE II; CASPASE 3; INTERLEUKIN 6; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ABDOMINAL SURGERY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER TISSUE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFECT; ENZYME ACTIVITY; FOLLOW UP; INVESTIGATIVE PROCEDURES; KIDNEY INJURY; KIDNEY PARENCHYMA; KIDNEY PERFUSION; LIGATION; MALE; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; SEPSIS; SHOCK; SINGLE DRUG DOSE; SPRAGUE DAWLEY RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; KIDNEY; PATHOLOGY; VASCULARIZATION;

RATTUS;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; CARBONIC ANHYDRASE II; DIPHOSPHONATES; IMIDAZOLES; INTERLEUKIN-6; KIDNEY; MALE; NITRIC OXIDE; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84924429080     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/JEnvironPatholToxicolOncol.2015012424     Document Type: Article

References (36)

1. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003 Nov 1;21(21):4042-57.
2. Nowacka-Cieciura E, Cieciura T, Baczkowska T, Kozińska-Przybył O, Tronina O, Chudziński W, Pacholczyk M, Durlik M. Bisphosphonates are effective prophylactic of early bone loss after renal transplantation. Transplant Proc. 2006 Jan-Feb;38(1):165-67.
3. Derenne S, Amiot M, Barillé S, Collette M, Robillard N, Berthaud P, Harousseau JL, Bataille R. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res. 1999 Dec;14(12):2048-56.
4. Koçer G, Nazıroğlu M, Çelik Ö, Önal L, Özçelik D, Koçer M, Koçer M, Sönmez TT. Basic fibroblast growth factor attenuates bisphosphonate-induced oxidative injury but decreases zinc and copper levels in oral epithelium of rat. Biol Trace Elem Res. 2013 Jun;153(1-3):251-56.
5. Muratsu D, Yoshiga D, Taketomi T, Onimura T, Seki Y, Matsumoto A, Nakamura S. Zoledronic acid enhances lipopolysaccharide-stimulated proinflammatory reactions through controlled expression of SOCS1 in macrophages. PLoS One. 2013 Jul 9;8(7):e67906.
6. Tauro M, Loiodice F, Ceruso M, Supuran CT, Tortorella P. Dual carbonic anhydrase/matrix metalloproteinase inhibitors incorporating bisphosphonic acid moieties targeting bone tumors. Bioorg Med Chem Lett. 2014 Jun 15;24(12):2617-20.
7. Tauro M, Loiodice F, Ceruso M, Supuran CT, Tortorella P. Arylamino bisphosphonates: potent and selective inhibitors of the tumor-associated carbonic anhydrase XII. Bioorg Med Chem Lett. 2014 Apr 15;24(8):1941-43.
8. Sun X, Soleimani M, Petrovic S. Decreased expression of Slc26a4 (Pendrin) and Slc26a7 in the kidneys of carbonic anhydrase II-deficient mice. Cell Physiol Biochem. 2008;21(1-3):95-108.
9. Cure E, Cure MC, Tumkaya L, Kalkan Y, Aydin I, Kirbas A, Yilmaz A, Yuce S, Gokce MF. Topiramate ameliorates abdominal aorta cross-clamping induced liver injury in rats. Saudi J Gastroenterol. 2014 Sep-Oct;20(5):297-303.
10. Lotan D, Eisenkraft A, Jacobsson JM, Bar-Yosef O, Kleta R, Gal N, Raviv-Zilka L, Gore H, Anikster Y. Clinical and molecular findings in a family with the carbonic anhydrase II deficiency syndrome. Pediatr Nephrol. 2006 Mar;21(3):423-26.
11. Clarkson MR, Friedewald JJ, Eustace JA, Rabb H. Acute kidney injury. In: Brenner BM, Livine SA, eds. Brenner & Rector’s the kidney. 8th ed. Philadelphia: WB Saunders; 2008. pp. 943-86.
12. Kellum JA. Acute kidney injury. Crit Care Med. 2008 Apr;36(4 Suppl):S141-45.
13. Donnahoo KK, Meldrum DR, Shenkar R, Chung CS, Abraham E, Harken AH. Early renal ischemia, with or without reperfusion, activates NF kappa B and increases TNF-alpha bioactivity in the kidney. J Urol. 2000 Apr;163(4): 1328-32.
14. Sancaktutar AA, Bodakci MN, Hatipoglu NK, Soylemez H, Basarılı K, Turkcu G.The protective effects of pomegranate extracts against renal ischemia-reperfusion injury in male rats. Urol Ann. 2014 Jan;6(1):46-50.
15. Sutton TA, Fisher CJ, Molitoris BA. Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Int. 2002 Nov;62(5):1539-49.
16. Ysebaert DK, De Greef KE, De Beuf A, Van Rompay AR, Vercauteren S, Persy VP, De Broe ME. T cells as mediators in renal ischemia/reperfusion injury. Kidney Int. 2004 Aug;66(2):491-96.
17. Parks DA, Granger DN. Contributions of ischemia and reperfusion to mucosal lesion formation. Am J Physiol. 1986 Jun;250(6 Pt 1):G749-53.
18. Tsai SH, Huang PH, Peng YJ, Chang WC, Tsai HY, Leu HB, Chen JW, Lin SJ. Zoledronate attenuates angiotensin II-induced abdominal aortic aneurysm through inactivation of Rho/ROCK-dependent JNK and NF-κB pathway. Cardiovasc Res. 2013 Dec 1;100(3):501-10.
19. Weiss HM, Pfaar U, Schweitzer A, Wiegand H, Skerjanec A, Schran H. Biodistribution and plasma protein binding of zoledronic acid. Drug Metab Dispos. 2008 Oct;36(10):2043-49.
20. Oyar EÖ, Kiriş I, Gülmen S, Ceyhan BM, Cüre MC, Delibaş N, Lortlar N, Okutan H. The protective effect of adrenomedullin on renal injury, in a model of abdominal aorta cross-clamping. Thorac Cardiovasc Surg. 2012 Feb;60(1):5-10.
21. Cure E, Cumhur Cure M, Tumkaya L, Kalkan Y, Aydin I, Kirbas A, Yilmaz A, Yuce S, Yücel AF. Adalimumab ameliorates abdominal aorta cross clamping which induced liver injury in rats. Biomed Res Int. 2014;2014:907915.
22. Kassi G, Papamichael K, Papaioannou G, Giagourta I, Thanou S, Triantaphyllopoulou M, Zapanti E, Papandroulaki F, Ktena V, Karga H. Cytokines and insulin resistance after zoledronic acid-induced acute phase response. Immunol Invest. 2014;43(6):544-55.
23. Çankaya M, Cizmeci Şenel F, Kadioglu Duman M, Muci E, Dayisoylu EH, Balaban F. The effects of chronic zoledronate usage on the jaw and long bones evaluated using RANKL and osteoprotegerin levels in an animal model. Int J Oral Maxillofac Surg. 2013 Sep;42(9):1134-39.
24. Mozzati M, Martinasso G, Maggiora M, Scoletta M, Zambelli M, Carossa S, Oraldi M, Muzio G, Canuto RA. Oral mucosa produces cytokines and factors influencing osteoclast activity and endothelial cell proliferation, in patients with osteonecrosis of jaw after treatment with zoledronic acid. Clin Oral Investig. 2013 May;17(4):1259-66.
25. Rodrigues FA, Prata MM, Oliveira IC, Alves NT, Freitas RE, Monteiro HS, Silva JA, Vieira PC, Viana DA, Libório AB, Havt A. Gingerol fraction from Zingiber officinale protects against gentamicin-induced nephrotoxicity. Antimicrob Agents Chemother. 2014;58(4): 1872-78.
26. Karabulut AB, Gul M, Karabulut E, Kiran TR, Ocak SG, Otlu O. Oxidant and antioxidant activity in rabbit livers treated with zoledronic acid. Transplant Proc. 2010 Nov;42(9):3820-22.
27. Ozbek E. Induction of oxidative stress in kidney. Int J Nephrol. 2012;2012:465897.
28. Al-Kahtani MA, Abdel-Moneim AM, Elmenshawy OM, El-Kersh MA. Hemin attenuates Cisplatin-induced acute renal injury in male rats. Oxid Med Cell Longev. 2014;2014:476430.
29. Cure E, Kirbas A, Tumkaya L, Cure MC, Sahin OZ, Kalkan Y, Yuce S, Altuner D. Effect of infliximab against cisplatin-induced nephrotoxicity. Saudi Med J. 2014 Sep;35(9):953-58.
30. Liu LC, Xu WT, Wu X, Zhao P, Lv YL, Chen L. Overexpression of carbonic anhydrase II and Ki-67 proteins in prognosis of gastrointestinal stromal tumors. World J Gastroenterol. 2013 Apr 28;19(16):2473-80.
31. Sh Ali AA, Al-Mashta SA. Cerebral calcification, osteopetrosis and renal tubular acidosis: is it carbonic anhydrase-II deficiency? Saudi J Kidney Dis Transpl. 2013 May;24(3):561-65.
32. Reshadat S, Nikray R, Alord S, Shackebaei D, Godini A, Hesari M. The effects of acetazolamide on ischemia reperfused isolated hearts of 2- and 8-week-old rabbits. Saudi Med J. 2012 Mar;33(3):250-55.
33. Aydogan A, Kocer G, Ozmen O, Kocer M, Onal L, Koskan O. Immunohistochemical expression of caspase-3, caspase-5, caspase-7 and apoptotic protease-activating factor-1 (APAF-1) in the liver and kidney of rats exposed to zoledronic acid (ZOL) and basic fibroblast growth factor (bFGF). Vet Q. 2014 Jun 19:1-6.
34. Mohamed Ael-H, Lasheen NN. Comparative study on the protective role of vitamin C and L-arginine in experimental renal ischemia reperfusion in adult rats. Int J Physiol Pathophysiol Pharmacol. 2014 Oct 11;6(3):153-65.
35. Thurman JM. Triggers of inflammation after renal ischemia/reperfusion. Clin Immunol. 2007 Apr;123(1):7-13.
36. Takada M, Nadeau KC, Shaw GD, Marquette KA, Tilney NL. The cytokine-adhesion molecule cascade in ischemia/ reperfusion injury of the rat kidney. Inhibition by a soluble P-selectin ligand. J Clin Invest. 1997 Jun 1;99(11):2682-90.